Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Achieve Life Sciences (ACHV) Other financing activities (2020 - 2025)

Achieve Life Sciences (ACHV) has disclosed Other financing activities for 3 consecutive years, with $3.8 million as the latest value for Q2 2025.

Quarterly Other financing activities changed N/A to $3.8 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Jun 2025, changed N/A year-over-year, with the annual reading at $20000.0 for FY2022, N/A changed from the prior year.
Other financing activities for Q2 2025 was $3.8 million at Achieve Life Sciences, up from $20000.0 in the prior quarter.
The five-year high for Other financing activities was $3.8 million in Q2 2025, with the low at $20000.0 in Q1 2022.